• payroll and personnel expenses, including benefits, stock-based compensation and travel expenses, for our research and development functions;

filing / Jul 9, 2026 / receipt

Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of May 31, 2026.

filing / Jul 9, 2026 / receipt

If additional capital is not available, failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives.

filing / Jul 9, 2026 / receipt

• payroll and personnel expenses, including benefits, stock-based compensation and travel expenses, for our research and development functions;

filing / Apr 8, 2026 / receipt

There was also an increase in compensation and related personnel costs due to an increase in headcount. 29 Table of Contents General and Administrative Expenses Our general and administrative expenses increased by $3.0 million during the three months ended February 28, 2026, compared to the three months ended February 28, 2025.

filing / Apr 8, 2026 / receipt

There was an increase in compensation and related personnel costs due to an increase in headcount. Liquidity and Capital Resources Sources of Liquidity In July 2020, we closed our initial public offering (IPO) and issued 12,550,000 shares of our common stock (including the exercise by the underwriters of their option to purchase an additional 1,550,000 shares of common stock in August 2020) at a price to the pu

filing / Apr 8, 2026 / receipt

Based on their evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of February 28, 2026.

filing / Apr 8, 2026 / receipt

If additional capital is not available, failure to generate sufficient cash flows from operations, raise additional capital and reduce discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives.

filing / Apr 8, 2026 / receipt

Associate Director, electronic Quality Management System (eQMS) | {"ats": "greenhouse", "city": "Brisbane", "state": "CA", "job_id": "8788376002", "remote": false, "category": "other", "function": "re

company_statement / Sep 9, 2026 / receipt

Director, Nonclinical Toxicology Operations | {"ats": "greenhouse", "city": "Brisbane", "state": "CA", "job_id": "8785509002", "remote": false, "category": "other", "function": "operations", "location

company_statement / Sep 8, 2026 / receipt

Senior Administrative Assistant, R&ED | {"ats": "greenhouse", "city": "Brisbane", "state": "CA", "job_id": "8785032002", "remote": false, "category": "other", "function": "other", "location": "Brisban

company_statement / Sep 7, 2026 / receipt

Senior Manager/Associate Director, Regulatory Affairs (Strategy, Hematology Oncology) | {"ats": "greenhouse", "city": "Brisbane", "state": "CA", "job_id": "8785500002", "remote": false, "category": "o

company_statement / Sep 7, 2026 / receipt